Literature DB >> 3769384

Influence of food on the bioavailability of spironolactone.

H W Overdiek, F W Merkus.   

Abstract

Nine healthy volunteers received a single oral dose of 200 mg spironolactone, once during fasting conditions and once immediately after a standardized breakfast. Serum concentrations of spironolactone and its metabolites 7 alpha-thiomethylspirolactone, 6 beta-hydroxy-7 alpha-thiomethylspirolactone, and canrenone were determined by HPLC for 24 hours after dosing. By taking spironolactone with food, the mean (+/- SD) AUC (0 to 24 hours) of the parent drug increased from 288 +/- 138 (empty stomach) to 493 +/- 105 ng X ml-1 X hr (P less than 0.001). The AUC (0 to 24 hours) of the three metabolites together also increased significantly from 8511 +/- 2062 (empty stomach) to 11219 +/- 2471 ng X ml-1 X hr (P less than 0.01). The mean (+/- SD) percent increase in AUC (0 to 24 hours) of spironolactone when it was given with food, compared with the ingestion on an empty stomach (95.4% +/- 66.9%), was much more pronounced than the corresponding increase of 7 alpha-thiomethylspirolactone (45.4% +/- 33.7%), 6 beta-hydroxy-7 alpha-thiomethylspiro-lactone (21.8% +/- 21.5%), and canrenone (40.7% +/- 26.3%). These observations indicate that food promotes the absorption of spironolactone and possibly decreases its first-pass metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769384     DOI: 10.1038/clpt.1986.219

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  The influence of nutrition on the systemic availability of drugs. Part I: Drug absorption.

Authors:  I Walter-Sack
Journal:  Klin Wochenschr       Date:  1987-10-01

Review 2.  The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.

Authors:  I Walter-Sack
Journal:  Klin Wochenschr       Date:  1987-11-02

3.  Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone.

Authors:  Miranda E Good; Yu-Hsin Chiu; Ivan K H Poon; Christopher B Medina; Joshua T Butcher; Suresh K Mendu; Leon J DeLalio; Alexander W Lohman; Norbert Leitinger; Eugene Barrett; Ulrike M Lorenz; Bimal N Desai; Iris Z Jaffe; Douglas A Bayliss; Brant E Isakson; Kodi S Ravichandran
Journal:  Circ Res       Date:  2017-12-13       Impact factor: 17.367

4.  Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.

Authors:  C S Cook; C L Hauswald; G L Schoenhard; C E Piper; A Patel; F M Radzialowski; J D Hribar; W Aksamit; P Finnegan; R H Bible
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

Review 5.  Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.

Authors:  Domenic A Sica
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

6.  Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.

Authors:  João Pedro Ferreira; Nicolas Girerd; Pedro Bettencourt Medeiros; Mário Santos; Henrique Cyrne Carvalho; Paulo Bettencourt; David Kénizou; Javed Butler; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2015-11-28       Impact factor: 5.460

Review 7.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

8.  Improved bioavailability from a spironolactone beta-cyclodextrin complex.

Authors:  N T Yusuff; P York; H Chrystyn; P N Bramley; R D Swallow; B R Tuladhar; M S Losowsky
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 10.  Mineralocorticoid receptor antagonists and endothelial function.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Curr Opin Investig Drugs       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.